Daiichi Sankyo Co Ltd (4568) - Comprehensive analysis
Daiichi Sankyo is a global leader in antibody-drug conjugates (ADCs) for cancer treatment. Its flagship product, Enhertu, is a HER2-targeting ADC that has become a transformative therapy for certain HER2-expressing cancers. Additionally, Daiichi has a pipeline of other ADC candidates targeting various cancers. We consider the shares to be modestly undervalued based on our cautious evaluation of the currently available clinical data; however, we anticipate share price volatility due to the company's reliance on future clinical readouts. In September, a disappointing result for Dato-DXd (a TROP2-targeting ADC) in second-line lung cancer negatively impacted Daiichi’s near-term growth outlook. Nevertheless, we believe the company will continue to experience strong growth, primarily driven by Enhertu.
MarketAnalysis
